Clinical Trials in Minneapolis

Showing 6781-6800 of 11,007 trials

HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or Lymphoma

NCT02370160

This is a phase I/II study of DT2219 for the treatment of relapsed or refractory CD19 (+) and/or CD 22 (+) B-lineage leukemia and lymphoma. The study consists of two phases - a phase I dose/schedule finding component using the maximum tolerated dose identified during the previous phase I study, but with a higher number of doses and a two-stage phase II extension component to confirm safety and make a preliminary determination of the activity level by disease using the dose identified in phase I.

Refractory B-Lineage LeukemiaRelapsed B-Lineage LeukemiaRefractory B-Lineage Lymphoma+1 more

Masonic Cancer Center, University of Minnesota18 participantsStarted Dec 2015

Minneapolis, Minnesota, United States

TERMINATEDPhase 3< 1 mile

Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes

NCT02556203

To assess whether a rivaroxaban-based anticoagulation strategy, following successful TAVR, compared to an antiplatelet-based strategy, is superior in reducing death or first thromboembolic events (DTE). To assess the primary bleeding events (PBE) of the rivaroxaban-based strategy compared to an antiplatelet-based strategy, following TAVR.

Transcatheter Aortic Valve Replacement

Bayer1,653 participantsStarted Dec 2015

Los Angeles, California, United States • Washington D.C., District of Columbia, United States • Clearwater, Florida, United States +137 more locations

HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or Lymphoma

Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes

Find Trials by Condition in Minneapolis

Biomarker Feedback for Smoking Cessation

Assessing the Effects Of Treadmill On LPA, Sitting Time, and Cardiovascular Risk

Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry

P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis

Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee

A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness

Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers

A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg

Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer

Study to Evaluate DNL201 in Subjects With Parkinson's Disease

Safety and Tolerability of TAR-302-5018 in Subjects With Neurogenic Detrusor Overactivity Resulting From Spinal Cord Injury

Prospective, Multi-Center All-Comer Biliary Canadian WallFlex Registry

Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA

COmedication Study Assessing Mono- and cOmbination Therapy With Levodopa-carbidopa inteStinal Gel

Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid Leukemia

Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer

A Study of Gene Polymorphisms Associated With Specific Presentations of Sexual Addiction

Radiesse® Safety Study For the Treatment of Hands